This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA et al. Acute myeloid leukemia, version 2. J Natl Compr Canc Netw 2013; 11: 1047–1055.
Mattison R, Luger S, Lazarus H . New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia. Curr Opin Hematol 2013; 20: 93–99.
Hussein K, Jahagirdar B, Gupta P, Burns L, Larsen K, Weisdorf D . Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia. Am J Hematol 2008; 83: 446–450.
Morris TA, DeCastro CM, Diehl LF, Gockerman JP, Lagoo AS, Li Z et al. Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia. Leuk Res 2013; 37: 28–31.
Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey E . Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica 2008; 93: 1263–1265.
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Group study. Blood 2000; 96: 4075–4083.
Othus M, Sudipto M, Sekeres M, Godwin J, Anderson J, Petersdorf S et al. Prediction of CR on reinduction in patients with newly diagnosed acute myeloid leukemia given intensive induction regimens; a report from SWOG and Cleveland Clinic. Blood 2013 122: 3924 (ASH Abstract 2013).
Vainstein V, Buckley SA, Shukron O, Estey EH, Abkowitz JL, Wood BL et al. Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia 2014; 28: 713–716.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Yezefski, T., Xie, H., Walter, R. et al. Value of routine ‘day 14’ marrow exam in newly diagnosed AML. Leukemia 29, 247–249 (2015). https://doi.org/10.1038/leu.2014.268
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.268
This article is cited by
-
Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia
Journal of Cancer Research and Clinical Oncology (2023)